|Bid||0.5800 x 800|
|Ask||0.6500 x 1000|
|Day's Range||0.5700 - 0.6260|
|52 Week Range||0.2500 - 0.7500|
|Beta (5Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.38|
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need, today announced that it submitted an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for its SYN-020 Intestinal Alkaline Phosphatase ("IAP") program. The IND application supports an initial indication of SYN-020 for the treatment of radiation enteropathy secondary to pelvic cancer therapy. Under the IND application, the Company intends to conduct a Phase 1 single ascending dose study in healthy volunteers, designed to evaluate SYN-020 for safety, tolerability, and pharmacokinetic parameters.
Q1 2020 Synthetic Biologics Inc Earnings Call
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need, today announced that it entered into an agreement with Massachusetts General Hospital ("MGH") granting the Company an option for an exclusive license to intellectual property and technology related to the use of intestinal alkaline phosphatase ("IAP") to maintain GI and microbiome health, diminish systemic inflammation, and treat age-related diseases. If executed, the Company plans to use this license in the advancement of an expanded clinical development program for SYN-020, the Company's proprietary recombinant version of bovine IAP currently in pre-clinical development.